Effect of Parenteral Selenium Supplementation in Critically Ill Patients: A Systematic Review and Meta-Analysis

Abstract

BackgroundIt is currently unclear whether parenteral selenium supplementation should be recommended in the management of critically ill patients. Here we conducted a systematic review and meta-analysis to assess the efficacy of parenteral selenium supplementation on clinical outcomes.Methods/Principal FindingsRandomized trials investigating parenteral selenium supplementation administered in addition to standard of care to critically ill patients were included. CENTRAL, Medline, EMBASE, the Science Citation Index, and CINAHL were searched with complementary manual searches. The primary outcome was all-cause mortality. Trials published in any language were included. Two authors independently extracted data and assessed trial quality. A third author was consulted to resolve disagreements and for quality assurance. Twelve trials were included and meta-analysis was performed on nine trials that recruited critically ill septic patients. These comprised 965 participants in total. Of these, 148 patients (30.7%) in the treatment groups, and 180 patients (37.3%) in control groups died. Parenteral selenium treatment significantly reduced all-cause mortality in critically ill patients with sepsis (relative risk [RR] 0.83, 95% CI 0.70–0.99, p = 0.04, I2 = 0%). Subgroup analyses demonstrated that the administration schedule employing longer duration (RR 0.77, 95% CI 0.63–0.94, p = 0.01, I2 = 0%), loading boluses (RR 0.73, 95% CI 0.58–0.94, p = 0.01, I2 = 0%) or high-dose selenium treatment (RR 0.77, 95% CI 0.61–0.99, p = 0.04, I2 = 0%) might be associated with a lower mortality risk. There was no evidence of adverse events.Conclusions/SignificanceParenteral selenium supplementation reduces risk of mortality among critically ill patients with sepsis. Owing to the varied methodological quality of the studies, future high-quality randomized trials that directly focus on the effect of adequate-duration of parenteral selenium supplementation for severe septic patients are needed to confirm our results. Clinicians should consider these findings when treating this high-risk population.Systematic Review RegistrationPROSPERO 2011; CRD42011001768

Neutralization of Mitochondrial Superoxide by Superoxide Dismutase 2 Promotes Bacterial Clearance and Regulates Phagocyte Numbers in Zebrafish

“…These attempts have had some success in restoring mitochondrial and organ function, reducing inflammatory signaling, and reducing oxidative stress (10,(63)(64)(65). Current therapies for septic patients that are critically ill include supplementation with antioxidants and have proven to help reduce the mortality rate of these patients (66)(67)(68). To the best of our knowledge, we are the first to use mitochondrion-targeted antioxidants in vivo as a method for improving the innate immune response to infection.…”

The impact of acute lung injury, ECMO and transfusion on oxidative stress and plasma selenium levels in an ovine model

“…Some studies have shown that selenium replacement in critically ill patients is beneficial in reducing infections (such as ventilator acquired pneumonia) and mortality [32,33]. This led us to investigate the impact of ECMO on plasma selenium levels.…”

Feeding the Critically Ill Patient

“…A recent, large, blinded RCT failed to demonstrate benefit from antioxidant combination, including selenium supplementation. However, the dose of selenium used was relatively low, and studies demonstrating benefit from selenium investigated cocktails containing selenium at higher doses (52)(53)(54). Use of probiotics has shown benefit in the ICU setting when commercially available products are provided, reducing ventilator-associated pneumonia, likelihood to acquire antibioticassociated diarrhea, pseudomembranous colitis, and possibly overall infections (55)(56)(57).…”